You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,888,544


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,888,544 protect, and when does it expire?

Patent 10,888,544 protects CERDELGA and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 10,888,544
Patent landscape, scope, and claims:
Title:Methods for treating Gaucher disease
Abstract: Methods for treating Gaucher disease in patients with renal or hepatic impairment.
Inventor(s): Li; Jing (Bridgewater, NJ), Peterschmitt; M. Judith (Watertown, MA), Kanamaluru; Vanaja (Bridgewater, NJ), Chen; Jun (Bridgewater, NJ), Gaemers; Sebastiaan J. M. (Naarden, NL), Rudin; Dan (Cambridge, MA)
Assignee: GENZYME CORPORATION (Cambridge, MA)
Application Number:16/219,064
Patent Claim Types:
see list of patent claims
Use;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,888,544

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 AB RX Yes Yes 10,888,544 ⤷  Subscribe LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT ⤷  Subscribe
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 AB RX Yes Yes 10,888,544 ⤷  Subscribe LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,888,544

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018386182 ⤷  Subscribe
Brazil 112020011056 ⤷  Subscribe
Canada 3083663 ⤷  Subscribe
China 111479591 ⤷  Subscribe
China 116139130 ⤷  Subscribe
Colombia 2020008319 ⤷  Subscribe
European Patent Office 3723809 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.